Therapeutic effects of repurposed therapies in non-small cell lung cancer: What is old is new again

Oncologist

Volumn 20, Issue 8, 2015, Pages 934-945

  Saxena, Ashish ^a   Becker, Daniel ^b   Preeshagul, Isabel ^c   Lee, Karen ^c   Katz, Elena ^c   Levy, Benjamin ^c,d  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^c BETH ISRAEL MEDICAL CENTER   (United States)

^d MOUNT SINAI HOSPITAL   (United States)

Author keywords

Drug repositioning; Itraconazole; Metformin; Non small cell lung cancer; Nonsteroidal anti inflammatory drug; Statins; Blocker

Indexed keywords

APRICOXIB; ATORVASTATIN; CELECOXIB; CIMETIDINE; EPIDERMAL GROWTH FACTOR RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; ITRACONAZOLE; METFORMIN; METOPROLOL; PEMETREXED; PROTEIN KINASE B; PROTEIN P53; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); SIMVASTATIN; WARFARIN; ANTINEOPLASTIC AGENT;

ABDOMINAL DISCOMFORT; ANGIOGENESIS; APOPTOSIS; ARTICLE; BRADYCARDIA; BRONCHOSPASM; CANCER STAGING; CARCINOGENESIS; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; CEREBROVASCULAR ACCIDENT; COGNITIVE DEFECT; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DIZZINESS; DOWN REGULATION; DRUG REPOSITIONING; FATIGUE; GASTROINTESTINAL HEMORRHAGE; GENE MUTATION; GRAPEFRUIT JUICE; HEADACHE; HEART INFARCTION; HEPATITIS; HUMAN; HYPERSENSITIVITY; HYPERTENSION; HYPOTENSION; LACTIC ACIDOSIS; LIVER TOXICITY; MEGALOBLASTIC ANEMIA; METASTASIS; MYALGIA; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; NON SMALL CELL LUNG CANCER; OXIDATIVE PHOSPHORYLATION; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; CARCINOMA, NON-SMALL-CELL LUNG; LUNG NEOPLASMS;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS;

EID: 84940038080     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2015-0064     Document Type: Article

References (82)

1. Paul SM, Mytelka DS, Dunwiddie CT et al. Howto improve R&D productivity: The pharmaceutical industry’s grand challenge. Nat Rev Drug Discov 2010;9:203–214.
2. Zamboni WC, Torchilin V, Patri AK et al. Best practices in cancer nanotechnology: Perspective from NCI nanotechnology alliance. Clin Cancer Res 2012;18:3229–3241.
3. Djalalov S, Beca J, Hoch JS et al. Cost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancer. J Clin Oncol 2014;32:1012–1019.
4. Rothwell PM, Wilson M, Elwin CE et al. Longterm effect of aspirin on colorectal cancer incidence and mortality: 20-Year follow-up of five randomised trials. Lancet 2010;376:1741–1750.
5. Neugut AI. Aspirin as adjuvant therapy for stage III colon cancer: Standard of care? JAMA InternMed 2014;174:739–741.
6. Jespersen CG, Nørgaard M, Friis S et al. Statin useand riskof prostate cancer:A Danish populationbased case-control study, 1997-2010. Cancer Epidemiol 2014;38:42–47.
7. Jiralerspong S, Palla SL, Giordano SH et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 2009;27:3297–3302.
8. Li X, Zhang N, Li Y et al. Effects of metformin and rosiglitazone on peripheral insulin resistance and b-cell function in obesity: A double-blind, randomized, controlled study. J Int Med Res 2011;39: 358–365.
9. Aljada A, Mousa SA. Metformin and neoplasia: Implications and indications. Pharmacol Ther 2012; 133:108–115.
10. Quinn BJ, Kitagawa H, Memmott RM et al. Repositioning metformin for cancer prevention and treatment. Trends Endocrinol Metab 2013;24: 469–480.
11. Morgillo F, Sasso FC, Della Corte CM et al. Metformin in lung cancer: Rationale for a combination therapy. Expert Opin Investig Drugs 2013;22: 1401–1409.
12. El-Mir MY, Nogueira V, Fontaine E et al. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem 2000;275:223–228.
13. Ashinuma H, Takiguchi Y, Kitazono S et al. Antiproliferative action ofmetformin in human lung cancer cell lines. Oncol Rep 2012;28:8–14.
14. Tseng SC, Huang YC, Chen HJ et al. Metformin-mediated downregulation of p38 mitogen-activated protein kinase-dependent excision repair cross-complementing 1 decreases DNA repair capacity and sensitizes human lung cancer cells to paclitaxel. Biochem Pharmacol 2013;85:583–594.
15. Lin CC, Yeh HH, Huang WL et al. Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMPactivated protein kinase pathway. Am J Respir Cell Mol Biol 2013;49:241–250.
16. Morgillo F, Sasso FC, Della Corte CM et al. Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines. Clin Cancer Res 2013;19: 3508–3519.
17. Li L, Han R, Xiao H et al. Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal. Clin Cancer Res 2014; 20:2714–2726.
18. Fasano M, Della Corte CM, Capuano A et al. A multicenter, open-label phase II study of metformin with erlotinib in second-line therapy of stage IVnonsmall- cell lung cancer patients: Treatment rationale and protocol dynamics of the METAL trial. Clin Lung Cancer 2015;16:57–59.
19. Memmott RM, Mercado JR, Maier CR et al. Metformin prevents tobacco carcinogen-induced lung tumorigenesis. Cancer Prev Res (Phila) 2010;3: 1066–1076.
20. Storozhuk Y, Hopmans SN, Sanli T et al. Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK. Br J Cancer 2013;108: 2021–2032.
21. Lai SW, Liao KF, Chen PC et al. Antidiabetes drugs correlatewith decreased risk of lung cancer: A population-based observation in Taiwan. Clin Lung Cancer 2012;13:143–148.
22. Tan BX, Yao WX, Ge J et al. Prognostic influence of metformin as first-line chemotherapy for advanced nonsmall cell lung cancer in patients with type 2 diabetes. Cancer 2011;117:5103–5111.
23. Lin JJ, Gallagher EJ, Sigel K et al. Survival of stage IV lung cancer patients with diabetes treated with metformin. Am J Respir Crit Care Med 2015; 191:448–454.
24. Sanchez-Cespedes M, Parrella P, Esteller M et al. Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res 2002; 62:3659–3662.
25. Ding L, Getz G, Wheeler DA et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008;455:1069–1075.
26. Zakikhani M, Dowling R, Fantus IG et al. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 2006;66: 10269–10273.
27. Shackelford DB, Abt E, Gerken L et al. LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. Cancer Cell 2013;23:143–158.
28. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. NEngl JMed 1998;339:1349–1357.
29. Thurnher M, Nussbaumer O, Gruenbacher G. Novel aspects of mevalonate pathway inhibitors as antitumor agents. Clin Cancer Res 2012;18: 3524–3531.
30. Pisanti S, Picardi P, Ciaglia E et al. Novel prospects of statins as therapeutic agents in cancer. Pharmacol Res 2014;88:84–98.
31. Bockorny B, Dasanu CA. HMG-CoA reductase inhibitors as adjuvant treatment for hematologic malignancies: What is the current evidence? Ann Hematol 2015;94:1–12.
32. Maksimova E, Yie TA, Rom WN. In vitro mechanisms of lovastatin on lung cancer cell lines as a potential chemopreventive agent. Lung 2008; 186:45–54.
33. Hwang KE, Na KS, Park DS et al. Apoptotic induction by simvastatin in human lung cancer A549 cells via Akt signaling dependent downregulation of survivin. Invest New Drugs 2011;29: 945–952.
34. Sanli T, Liu C, Rashid A et al. Lovastatin sensitizes lung cancer cells to ionizing radiation: Modulationofmolecular pathways of radioresistance and tumor suppression. J Thorac Oncol 2011;6: 439–450.
35. Chen J, Lan T, Hou J et al. Atorvastatin sensitizes human non-small cell lung carcinomas to carboplatin via suppression of AKT activation and upregulation of TIMP-1. Int J BiochemCell Biol 2012;44:759–769.
36. Park IH, Kim JY, Jung JI et al. Lovastatin overcomes gefitinib resistance in human non-small cell lung cancer cells with K-Ras mutations. Invest New Drugs 2010;28:791–799.
37. Hwang KE, Kwon SJ, Kim YS et al. Effect of simvastatin on the resistance to EGFR tyrosine kinase inhibitors in a non-small cell lung cancer with theT790Mmutation of EGFR. Exp Cell Res2014;323: 288–296.
38. Mantha AJ, Hanson JE, Goss G et al. Targeting the mevalonate pathway inhibits the function of the epidermal growth factor receptor. Clin Cancer Res 2005;11:2398–2407.
39. Zhao TT, Le Francois BG, Goss G et al. Lovastatin inhibits EGFR dimerization and AKT activation in squamous cell carcinoma cells: Potential regulation by targeting rho proteins. Oncogene 2010;29: 4682–4692.
40. AstraZeneca. Study to assess the effect of AZD9291 on the blood levels of simvastatin in patients with EGFRm1 NSCLC. NLM Identifier: NCT02197234. 2000. Available at http://www.clinicaltrials.gov/show/NCT02197234. Accessed August 1, 2014.
41. AstraZeneca. Study to assess the effect of AZD9291 on the blood levels of rosuvastatin, in patients with EGFRm1 non-small cell lung cancer. NLM Identifier: NCT02317016. 2000. Available at http://www.clinicaltrials.gov/show/NCT02317016. Accessed April 8, 2015.
42. Ottawa Hospital Research Institute, Ozmosis Research Inc. Phase I study of a statin 1 erlotinib for advanced solid malignancies with focus on squamous cell carcinomas and NSCLC. NLM Identifier: NCT00966472. 2000. Available at http://clinicaltrials.gov/show/NCT00966472. Accessed August 1, 2014.
43. Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancer-related mortality. N Engl J Med 2012;367:1792–1802.
44. Han JY, Lee SH, Yoo NJ et al. Arandomizedphase II study of gefitinib plus simvastatin versus gefitinib alone in previously treated patients with advanced non-small cell lung cancer. Clin Cancer Res 2011;17: 1553–1560.
45. Wang HM, Liao ZX, Komaki R et al. Improved survival outcomes with the incidental use of betablockers among patients with non-small-cell lung cancer treated with definitive radiation therapy. Ann Oncol 2013;24:1312–1319.
46. Cata JP, Villarreal J, Keerty D et al. Perioperative beta-blocker use and survival in lung cancer patients. J Clin Anesth 2014;26:106–117.
47. Aydiner A, Ciftci R, Karabulut S et al. Does beta-blocker therapy improve the survival of patients with metastatic non-small cell lung cancer? Asian Pac J Cancer Prev 2013;14: 6109–6114.
48. Rudin CM, Brahmer JR, Juergens RA et al. Phase 2 study of pemetrexed and itraconazole as second-line therapy for metastatic nonsquamous non-small-cell lung cancer. J Thorac Oncol 2013;8: 619–623.
49. National Cancer Center, Korea, Boehringer Ingelheim. BIBW 2992 plus simvastatin vs. BIBW 2992 in previously treated patients with advanced non-adenocarcinomatous NSCLC. NLM Identifier: NCT01156545. 2000. Available at http://clinicaltrials.gov/show/NCT01156545. Accessed August 1, 2014.
50. Thun MJ, Jacobs EJ, Patrono C. The role of aspirin in cancer prevention. Nat Rev Clin Oncol 2012;9:259–267.
51. Greenhough A, Smartt HJ, Moore AE et al. The COX-2/PGE2 pathway: Key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 2009;30: 377–386.
52. Liggett JL, Zhang X, Eling TE et al. Anti-tumor activity of non-steroidal anti-inflammatory drugs: Cyclooxygenase-independent targets. Cancer Lett 2014;346:217–224.
53. Liu LT, Chang HC, Chiang LC et al. Induction of RECK by nonsteroidal anti-inflammatory drugs in lung cancer cells. Oncogene 2002;21: 8347–8350.
54. Qiu R, Chen J, Sima J et al. NS398 induces apoptosis in non-small cell lung cancer cells. JCancer Res Clin Oncol 2012;138:119–124.
55. Kim BM, Won J, Maeng KA et al. Nimesulide, a selective COX-2 inhibitor, acts synergistically with ionizing radiation against A549 human lung cancer cells through the activation of caspase-8 and caspase-3. Int J Oncol 2009;34: 1467–1473.
56. Duffy CP, Elliott CJ, O’Connor RA et al. Enhancement of chemotherapeutic drug toxicity to human tumour cells in vitro by a subset of nonsteroidal anti-inflammatory drugs (NSAIDs). Eur J Cancer 1998;34:1250–1259.
57. O’Connor R, Heenan M, Connolly L et al. Increased anti-tumour efficacy of doxorubicin when combined with sulindac in a xenograft model of an MRP-1-positive human lung cancer. Anticancer Res 2004;24:457–464.
58. Krysan K, Reckamp KL, Sharma S et al. The potential and rationale for COX-2 inhibitors in lung cancer. Anticancer Agents Med Chem 2006;6: 209–220.
59. Khuri FR, Wu H, Lee JJ et al. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res 2001;7:861–867.
60. Csiki I, Morrow JD, Sandler A et al. Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: A phase II trial of celecoxib and docetaxel. Clin Cancer Res 2005;11:6634–6640.
61. Schneider BJ, Kalemkerian GP, Kraut MJ et al. Phase II study of celecoxib and docetaxel in nonsmall cell lung cancer (NSCLC) patients with progression after platinum-based therapy. J Thorac Oncol 2008;3:1454–1459.
62. Gadgeel SM, Ruckdeschel JC, Heath EI et al. Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFRTKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patientswith platinumrefractory nonsmall cell lungcancer (NSCLC). J ThoracOncol2007;2: 299–305.
63. Edelman MJ, Watson D, Wang X et al. Eicosanoid modulation in advanced lung cancer: Cyclooxygenase-2 expression is a positive predictive factor for celecoxib 1 chemotherapy—Cancer and Leukemia Group B Trial 30203. J Clin Oncol 2008;26: 848–855.
64. Groen HJ, Sietsma H, Vincent A et al. Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: The NVALT-4 study. J Clin Oncol 2011;29: 4320–4326.
65. Gridelli C, Gallo C, Ceribelli A et al. Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: The GEmcitabine- COxib in NSCLC (GECO) study. Lancet Oncol 2007;8: 500–512.
66. Koch A, Bergman B, Holmberg E et al. Effect of celecoxib on survival in patients with advanced nonsmall cell lung cancer: A double blind randomised clinical phase III trial (CYCLUS study) by the Swedish Lung Cancer Study Group. Eur J Cancer 2011;47: 1546–1555.
67. Gitlitz BJ, Bernstein E, Santos ES et al. A randomized, placebo-controlled, multicenter, biomarker-selected, phase 2 study of apricoxib in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Thorac Oncol 2014;9:577–582.
68. Edelman MJ, Tan MT, Fidler MJ et al. Randomized, double-blind, placebo-controlled,multicenter phase II study of the efficacy and safety of apricoxib in combination with either docetaxel or pemetrexed in patients with biomarker-selected non-small-cell lung cancer. J Clin Oncol 2015;33: 189–194.
69. Sloan EK, Priceman SJ, Cox BF et al. The sympathetic nervous system induces a metastatic switch in primary breast cancer. CancerRes 2010;70: 7042–7052.
70. Park PG, Merryman J, Orloff M et al. Beta-adrenergic mitogenic signal transduction in peripheral lung adenocarcinoma: Implications for individuals with preexisting chronic lung disease. Cancer Res 1995;55:3504–3508.
71. Sood AK, Bhatty R, Kamat AA et al. Stress hormone-mediated invasion of ovarian cancer cells. Clin Cancer Res 2006;12:369–375.
72. Armaiz-Pena GN, Allen JK, Cruz A et al. Src activation by b-adrenoreceptors is a key switch for tumour metastasis. Nat Commun 2013;4: 1403.
73. Al-Wadei HA, Al-Wadei MH, Schuller HM. Cooperative regulation of non-small cell lung carcinoma by nicotinic and beta-adrenergic receptors: A novel target for intervention. PLoS One 2012;7:e29915.
74. Schuller HM, Tithof PK, Williams M et al. The tobacco-specific carcinogen 4-(methylnitrosamino)- 1-(3-pyridyl)-1-butanone is a beta-adrenergic agonist and stimulates DNA synthesis in lung adenocarcinoma via beta-adrenergic receptor-mediated release of arachidonic acid. Cancer Res 1999;59: 4510–4515.
75. Kim J, Tang JY, Gong R et al. Itraconazole, a commonly used antifungal that inhibits hedgehog pathway activity and cancer growth. Cancer Cell 2010;17:388–399.
76. Kim J, Aftab BT, Tang JY et al. Itraconazole and arsenic trioxide inhibit hedgehog pathway activation and tumor growth associated with acquired resistance tosmoothenedantagonists. CancerCell2013;23:23–34.
77. Kim DJ, Kim J, Spaunhurst K et al. Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma. J Clin Oncol 2014; 32:745–751.
78. Shim JS, Liu JO. Recent advances in drug repositioning for the discovery of new anticancer drugs. Int J Biol Sci 2014;10:654–663.
79. Aftab BT, Dobromilskaya I, Liu JO et al. Itraconazole inhibits angiogenesis and tumor growth in non-small cell lung cancer. Cancer Res 2011;71:6764–6772.
80. Sidney Kimmel Comprehensive Cancer Center. A randomized phase II study of SUBATM-itraconazole in patients with untreated squamous NSCLC. NLM Identifier: NCT01752023. 2000. Available at http://clinicaltrials.gov/show/NCT01752023. Accessed April 5, 2015.
81. Gupta SC, Sung B, Prasad S et al. Cancer drug discovery by repurposing: Teaching new tricks to old dogs. Trends Pharmacol Sci 2013;34: 508–517.
82. Mullard A. Drug repurposing programmes get lift off. Nat Rev Drug Discov 2012;11:505–506.